Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib PK in Hepatic Impairment
NCT03465059Phase 1Completed
- Sponsor
- BeiGene
- Start
- May 2018
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanubrutinib in mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), chronic lymphocytic leukemia (CLL) and 2 more (4 arms), sponsored by BeiGene. Primary endpoint: Plasma concentration of Zanubrutinib. Started May 2018; status: completed.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)Waldenstrom macroglobulinemia (WM)chronic lymphocytic leukemia (CLL)marginal zone lymphoma (MZL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03465059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465059.